Compass Therapeutics (CMPX) Operating Income (2023 - 2025)
Historic Operating Income for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to -$15.8 million.
- Compass Therapeutics' Operating Income fell 2923.44% to -$15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$71.4 million, marking a year-over-year decrease of 2881.31%. This contributed to the annual value of -$56.6 million for FY2024, which is 1243.37% down from last year.
- Latest data reveals that Compass Therapeutics reported Operating Income of -$15.8 million as of Q3 2025, which was down 2923.44% from -$21.1 million recorded in Q2 2025.
- In the past 5 years, Compass Therapeutics' Operating Income registered a high of -$9.7 million during Q1 2023, and its lowest value of -$21.1 million during Q2 2025.
- Its 3-year average for Operating Income is -$14.7 million, with a median of -$15.0 million in 2024.
- As far as peak fluctuations go, Compass Therapeutics' Operating Income crashed by 262.45% in 2024, and later plummeted by 4068.91% in 2025.
- Over the past 3 years, Compass Therapeutics' Operating Income (Quarter) stood at -$15.4 million in 2023, then decreased by 7.67% to -$16.6 million in 2024, then grew by 4.57% to -$15.8 million in 2025.
- Its last three reported values are -$15.8 million in Q3 2025, -$21.1 million for Q2 2025, and -$18.0 million during Q1 2025.